Abstract
Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Infectious Disorders - Drug Targets
Title: New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors
Volume: 9 Issue: 3
Author(s): S. M. Tomlinson, R. D. Malmstrom and S. J. Watowich
Affiliation:
Keywords: Dengue virus (DENV), family Flaviviridae, Dengue Protease Inhibitors, DENV vaccines, malaria, Mosquitoes
Abstract: Dengue virus (DENV), a member of the family Flaviviridae, presents a tremendous threat to global health since an estimated 2.5 billion people worldwide are at risk for epidemic transmission. DENV infections are primarily restricted to sub-tropical and tropical regions; however, there is concern that the virus will spread into new regions including the United States [1]. There are no approved antiviral drugs or vaccines to combat dengue infection, although DENV vaccines have entered Phase 3 clinical trials. Drug discovery and development efforts against DENV and other viral pathogens must overcome specificity, efficacy, safety, and resistance challenges before the shortage of licensed drugs to treat viral infections can be relieved. Current drug discovery methods are largely inefficient and thus relatively ineffective at tackling the growing threat to public health presented by emerging and remerging viral pathogens. This review discusses current and newly implemented structure-based computational efforts to discover antivirals that target the DENV NS3 protease, although it is clear that these computational tools can be applied to most disease targets.
Export Options
About this article
Cite this article as:
Tomlinson M. S., Malmstrom D. R. and Watowich J. S., New Approaches to Structure-Based Discovery of Dengue Protease Inhibitors, Infectious Disorders - Drug Targets 2009; 9 (3) . https://dx.doi.org/10.2174/1871526510909030327
DOI https://dx.doi.org/10.2174/1871526510909030327 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Pharmacological Modulation of the State of Awareness in Patients with Disorders of Consciousness: An Overview
Current Pharmaceutical Design Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Isolation of Antibodies From Non-Human Primates for Clinical Use
Current Drug Discovery Technologies Information Disclosed in Patent Documents being the Source to Address Emergencies: A Strategy to Achieve Technological Developments Addressing COVID-19
Recent Patents on Biotechnology Gene Cloning and Homology Modeling of the 3-Oxoacyl-ACP Synthase from Aeromonas hydrophila for Drug Discovery
Letters in Drug Design & Discovery Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry Anti-NMDA Receptor Encephalitis in Psychiatry
Current Psychiatry Reviews Basic Approaches in Therapy of Multiple Sclerosis (MS) and Related Diseases: Current Achievement and Prospective
Central Nervous System Agents in Medicinal Chemistry Etiopathogenesis, Classical Immunotherapy and Innovative Nanotherapeutics for Inflammatory Neurological Disorders
Current Nanoscience Antiviral Strategies: The Present and Beyond
Current Molecular Pharmacology Infection, Infectious Agents and Vascular Disease
Reviews on Recent Clinical Trials Microbiota Regulation of Inflammatory Bowel Disease
Inflammation & Allergy - Drug Targets (Discontinued) Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design <i>In Silico</i> Approach to Predict the SARS-COV2 Derived Candidate MiRNAs as a Potential Antiviral Therapy
Current Drug Therapy Mechanisms of Mononuclear Phagocyte Recruitment in Alzheimers Disease
CNS & Neurological Disorders - Drug Targets CIITA and the MHCII Enhanceosome in the Regulation of MHCII Expression
Current Genomics How Does Indoleamine 2,3-Dioxygenase Contribute to HIV-Mediated Immune Dysregulation
Current Drug Metabolism Role of Cytokines in Neurological Disorders
Current Medicinal Chemistry Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review
Current Medicinal Chemistry